10-year follow-up after standardised treatment for Achilles tendinopathy

Finn Johannsen,1,2 Signe Jensen,2 Eva Wetke3

ABSTRACT

Background Achilles tendinopathy is a common and often long-lasting injury. We present a 10-year follow-up on a pragmatic study on Achilles tendinopathy treated with controlled exercises supplemented with corticosteroid injections if necessary in order to continue training.

Methods All patients who completed the original study (n=93) were invited for a 10-year follow-up. 83% participated. Patients were evaluated with ultrasound scanning (n=58) and with a questionnaire (n=77) using the same outcome measures as in the primary study. The 10-year overall outcome on a 4-point scale (excellent, good, fair, poor), other treatments and adverse event and present activity level were recorded.

Results Excellent outcome was reported in 63% and good outcome in 27%. 76% reported an activity level at 75%–100% of preinjury level. The average Victorian Institute of Sports Assessment-Achilles score for all patients was 84 (SD 19). 16% had surgery. Three ruptures occurred 5–8 years after the primary study. The improvement from entry to 6 months in the primary study was maintained until 10-year follow-up. Insertional tendinopathy did not differ from mid-substance tendinopathy in any outcome measure (short term and long term). We encountered no prognostic markers on ultrasound for the long-term outcome; however, present heterogeneity or increased flow resemble present pain. Thicken tendons seem to maintain their thickness despite improvement of symptoms.

Conclusion One to two corticosteroid injections are a safe and effective supplement to controlled exercises in the treatment of Achilles tendon pain with no signs of deterioration in the very long term. Mid-substance and insertional tendinopathies benefit equally from this treatment.

INTRODUCTION

Achilles tendinopathy (AT) is a common and often long-lasting injury. There are many recommended conservative treatment modalities for AT, meaning no one is really excellent. Eccentric exercises are often recommended,1 with reported improvement in 60%2–3 to 90%.4–6 Malliaras et al4 found that there was no clear evidence that favoured eccentric exercises over eccentric/concentric exercises. Beyer et al6 found that heavy slow resistance exercise three times a week was as good as daily eccentric exercises.8 Other studies have shown the effect of stretching exercises.6,9 Fredberg et al10 found good short-term effect of peritendinous injection of corticosteroid (CS), but an aggressive rehabilitation resulted in a relapse after 6 months.10 These randomised clinical efficacy trials have been performed by highly motivated physiotherapists and investigators seeking high compliance on selected motivated patients agreeing in supervised training, and it is doubtful that the same success rate can be achieved on all patients.11

Some studies have looked at the very long-term follow-up (5–8 years).12-14 At 5 years Silbernagel et al12 reported 65% were symptom-free,12 whereas van der Plas et al13 found only 39.7% without symptoms,13 and Paavola et al14 reported 59% symptom-free after 8 years.14

In 2004/2005 we performed a pragmatic study on all consecutive patients with AT being referred to one of two outpatient rheumatology clinics in Copenhagen, Denmark during a 10-month period.15 All patients were treated with the same treatment regimen regardless of the location of tendinopathy: reduced running and jumping activities, concentric/eccentric exercises, calf stretching, and if training was impossible due to too severe pain supplemented with one to three ultrasound-guided CS injections (1 mL Lidocaine 10 mg/mL and 1 mL methylprednisolone acetate 40 mg/mL) in order to continue the training. Twenty-four succeeded with training alone, 54 had one CS injection,
13 had two CS injections and 2 had three CS injections. At follow-up after 6 months, 94% had improved and 76% were symptom-free or had only slight symptoms. Bakkegaard et al have described the ultrasound scanning (US) findings in that study and found that heterogeneity, defined as clearly demarcated hypoechoic or hyperechoic areas within the tendon at the initial examination, was found to be a prognostic marker for poor clinical outcome at 6 months.

The objectives of this study were to investigate the very long-term result (10 years) of the patients included in our previous study and to investigate if CS injections influenced this outcome and also if US is useful for the very long-term prognosis.

MATERIALS AND METHODS

In the original study 113 consecutive patients were clinically diagnosed with AT. US confirmed the diagnosis. Eight juvenile and two pre-existing ruptures were excluded. Ten patients dropped out for various reasons, resulting in 93 patients completing the study. Sixty-eight were active in sports pre-injury with a mean of 5.3 hours of activity per week, but the activity level did not influence the outcome. Seventy-five with mid-substance tendinopathy and 18 with insertional tendinopathy improved equally from the treatment.

All patients who completed the original study (n=93) were invited 10 years after the last person finished the primary study, meaning that patients were invited 10 years and 0 month to 10 years and 10 months after finishing the primary study. Patients were invited to a physical examination including US and/or a questionnaire.

Patient involvement

Patients were not involved in setting the research agenda.

All patients were invited by phone or letter to participate in this follow-up. Seventy-seven (83%) participated, 19 answered our questionnaire by phone (n=14) or letter (n=5), and 58 showed up for examination including US (figure 1).

An independent investigator (SJ) evaluated the patients’ symptoms and function. We registered the weight, activity level in per cent compared with before the injury, change of sport and the reason, and global assessment of function over the past 10 years on a 4-grade scale—1: excellent, no physical limitations; 2: good, slight physical limitation; 3: fair, considerable physical limitations; and 4: poor, severe physical limitation, and whether the Achilles tendon was the reason for these limitations. They were also asked if they had experienced Achilles tendon rupture and if they had sought other treatment and received any CS injections after our study ended.

Symptoms were evaluated as in the primary study using a 100 mm Visual Analogue Scale. We recorded pain during function after doing 20 one-legged heel rises, pain at palpation by pinching the tendon gently between two fingers, and self-reported morning pain. In the primary study, we were not aware of a quantitative pain and function score, but for the 10-year follow-up we used the ‘Victorian Institute of Sports Assessment – Achilles’ (VISA-A), which recently was validated and reliability-tested in Danish-speaking patients with tendinopathy. These outcome measures were only assessed on patients showing up for clinical examination or by telephone contact for proper instruction.

The clinical examination consisted of US by one of the investigators of the primary study (FJ) using the same standards and definitions. The US machine used was Hi Vision Avius (Hitachi Medical Systems UK) with an 18–5 MHz linear array transducer. US diagnostics were performed with the patient lying prone face down with the feet hanging free over the edge and the ankle at approximately 90° dorsiflexion without tension to the tendon. The tendon was scanned longitudinally and transversally. The thickness was measured at the thickest part of the tendon on a transverse scan, which we have shown to be reliable. A colour Doppler was used to evaluate the flow according to the Newman Grading Scale (0–3) after the Doppler was calibrated to zero pixels at an asymptomatic area on the gastrocnemius part of the tendon. We were also looking for hypoechoic and hyperechoic changes within the tendon and for bursitis.

Statistics

Association between increased intratendinous flow, heterogeneity, insertional or intratendinous affection and function score, but for the 10-year follow-up we used the ‘Victorian Institute of Sports Assessment – Achilles’ (VISA-A), which recently was validated and reliability-tested in Danish-speaking patients with tendinopathy. These outcome measures were only assessed on patients showing up for clinical examination or by telephone contact for proper instruction.

The clinical examination consisted of US by one of the investigators of the primary study (FJ) using the same standards and definitions. The US machine used was Hi Vision Avius (Hitachi Medical Systems UK) with an 18–5 MHz linear array transducer. US diagnostics were performed with the patient lying prone face down with the feet hanging free over the edge and the ankle at approximately 90° dorsiflexion without tension to the tendon. The tendon was scanned longitudinally and transversally. The thickness was measured at the thickest part of the tendon on a transverse scan, which we have shown to be reliable. A colour Doppler was used to evaluate the flow according to the Newman Grading Scale (0–3) after the Doppler was calibrated to zero pixels at an asymptomatic area on the gastrocnemius part of the tendon. We were also looking for hypoechoic and hyperechoic changes within the tendon and for bursitis.
and tendon thickness both at the initial examination and at 10-year follow-up compared with 10-year outcome measured by VISA-A score was tested using non-paired t-test for dichotomous variables and by Pearson correlation for continuous variables.

Association between US measures initially and after 10 years was tested with Fisher's exact test for dichotomous variables and Pearson correlation for Gaussian distributed continuous variables, otherwise Spearman correlation.

Intergroup differences (0, 1 or 2 CS injections) in the 10-year outcome measures were calculated using one-way analysis of variance. For intragroup differences we used paired t-test.

RESULTS
Overall 63% reported excellent outcome with no physical limitation in the past 10 years. A further 27% reported only slight limitation. Overall 76% reported an activity level at 75%–100% of preinjury level, and the average VISA-A score for all patients was 84 (SD 19), and 64% were above 90. Twenty-two per cent had changed sport due to Achilles tendon problems.

Sixteen per cent had surgery, 10% for mid-substance tendinopathy and 43% for insertional tendinopathy. Three tendon ruptures were reported, one in each group (0, 1 and 2 CS injections). The patient in the 0 CS group had received six CS injections from another doctor before rupture. The other patients sustained their ruptures 5–8 years after the CS injection in our study and had had no other injections.

Patient characteristics at 10-year follow-up are presented in Table 1, divided into the three primary treatment groups.

The single patient with three CS injections is not included in the statistic analysis due to the small number. For comparison the average activity level compared with preinjury level of patients receiving, respectively, zero, one and two CS injections was 85%, 83% and 74% (no intergroup difference), and the average VISA-A scores were, respectively, 87 (SD 17), 85 (SD 16) and 76 (SD 27), with no intergroup differences.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Patients’ characteristics at 10-year follow-up divided into the three primary treatment groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 CS injection</td>
</tr>
<tr>
<td>n</td>
<td>20</td>
</tr>
<tr>
<td>Female</td>
<td>4</td>
</tr>
<tr>
<td>Age (SD)</td>
<td>56 (10.8)</td>
</tr>
<tr>
<td>Weight (SD)</td>
<td>83.9 (13.7)</td>
</tr>
<tr>
<td>Change of sport during 10 years</td>
<td>8</td>
</tr>
<tr>
<td>Due to Achilles tendon</td>
<td>4</td>
</tr>
<tr>
<td>Other treatment past 10 years</td>
<td></td>
</tr>
<tr>
<td>Operation</td>
<td>1</td>
</tr>
<tr>
<td>CS injection</td>
<td>3</td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
</tr>
<tr>
<td>Physical function past 10 years</td>
<td>(19 answers)</td>
</tr>
<tr>
<td>Excellent: no limitations</td>
<td>13 (68%)</td>
</tr>
<tr>
<td>Good: slight limitation</td>
<td>5 (26%)</td>
</tr>
<tr>
<td>Fair: large physical limitation</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Poor: severe physical limitation</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Activity level compared with preinjury level</td>
<td>(19 answers)</td>
</tr>
<tr>
<td>0%–24%</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>25%–49%</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>50%–74%</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>75%–100%</td>
<td>15 (79%)</td>
</tr>
<tr>
<td>VISA-A score</td>
<td>(19 answers)</td>
</tr>
<tr>
<td>0–49</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>50–74</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>75–89</td>
<td>4 (21%)</td>
</tr>
<tr>
<td>90–100</td>
<td>13 (68%)</td>
</tr>
</tbody>
</table>

Figure 2 Pain during activity, in the morning and by pinching is illustrated at entry, after 6 months and after 10 years. I bars illustrate SD. Groups 0, 1 and 2 had zero, one or two corticosteroid injections, respectively, in the primary study. All groups improved significantly from entry to 6 months and entry to 10 years, without significant changes from 6 months to 10 years. Group 2 was significantly different from the other groups at 10-year follow-up: VAS activity *p*=0.022, VAS morning *p*=0.016 compared with the other groups (one-way analysis of variance). CS, corticosteroid; VAS, Visual Analogue Scale.

Pain outcome measures
In figure 2 the pain outcome measures are presented at entry, at 6 months and at 10-year follow-up. All outcome measures improved significantly in the primary study from entry to 6 months for the total group of patients and for each subgroup of patients receiving zero, one or two CS injections. This improvement remained significant until 10-year follow-up for the total group as well as for each subgroup. However, comparing each subgroup at 10 years, the subgroup of patients receiving two CS injections scored significantly higher than the other treatment groups in pain during function (*p*<0.0001) and morning pain (*p*=0.013), but without significant difference in pain by pinching.

Insertional and mid-substance tendinopathies
Fourteen insertional and 63 mid-substance tendinopathies (defined as the thickest part of the tendon on US) were included in the follow-up and they had equal long-term outcome. VISA-A score for all patients with insertional tendinopathy was 90 (SD 10), for tendinopathy 1–2 cm above insertion was 87 (SD 17) and for mid-substance tendinopathy 80 (SD 21), with no intergroup differences. These scores included the 12 operated patients (6 insertional, 1 just above insertion, 5 mid-substance). Excluding the operated patients the VISA-A score for insertional tendinopathy was 90 (SD 6), tendinopathy 1–2 cm above insertion was 86 (SD 18) and for mid-substance tendinopathy 82 (SD 20), with no intergroup differences. These good results for insertional tendinopathy might be too optimistic as a big proportion (6/14) of these patients underwent surgery.

Ultrasound scanning
Figure 3 illustrates the change in thickness of the Achilles tendon. For the total group a significant decrease in thickness was found from entry to 6 months (*p*<0.0001) and from entry to 10 years (*p*=0.004); however, from 6 months to 10 years, thickness increased significantly (*p*=0.001). Only the two subgroups receiving CS injections showed a significant decrease from entry to 6 months (*p*<0.0001 and *p*=0.011, respectively), and the group receiving two CS injections showed significant worsening from 6 months to 10 years (*p*=0.012), and the group receiving one CS injection showed tendency to worsening (*p*=0.07).

Neither the tendon thickness at entry nor the tendon thickness at 10-year follow-up correlated with the 10-year VISA-A score (Spearman test), but as illustrated in figure 4 the thickness at entry and at 10-year follow-up correlated (*r*=0.56, *p*<0.0001, Pearson).

Heterogeneity or increased flow at entry did not predict poor outcome measured by VISA-A score, although increased flow grades 2–3 at 10-year follow-up had significantly poorer VISA-A score compared with grades 0–1 flow (*p*=0.0015). Also present heterogeneity showed a strong tendency to lower VISA-A score (*p*=0.070). We found no correlation in neither flow nor heterogeneity from entry to 10-year follow-up, but this could be explained by differences in the US machines and the development of more sensitive Doppler function in the newer machines.

The maximal tendon thickness measured by ultrasound scanning at entry, 6 months and 10 years. I bars illustrate SD. Groups 0, 1 and 2 had zero, one or two corticosteroid injections, respectively, in the primary study. Thickness decreased significantly from entry to 6 months for the total group and groups 1 and 2, and increased significantly from 6 months to 10 years for the total group and group 2.

**Figure 3**

**DISCUSSION**

Corticosteroid in AT

We have described the long-term effect of a treatment regimen for AT consisting of reduced loading, slowly progressive concentric and eccentric strengthening exercises, stretching exercises, supplemented with one to three CS injections if patients were unable to commence or progress in exercise. We have previously described the short-medium term (6 months) effectiveness of this treatment and found that 94% improved, and 77% with good or excellent effect. In the present study 90% reported excellent or good results after 10 years. This is in contrast to a study by Fredberg et al., who describe a poor outcome after CS injection after 6 months. A meta-analysis on CS injections for tendinopathy in general also confirms poor outcome in the long term. This could be due to the fact that most randomised controlled trial (RCT) studies on CS injections mainly use a single CS injection as monotherapy, whereas we used one to three CS injections as a supplement and only if necessary in order to proceed with a cautious and slowly progressive training protocol. Therefore it seems that CS might reduce warning signals and lead to too quick training progression, if training is not controlled by a cautious protocol.

Our very long-term results are comparable with other long-term follow-up studies. Paavola et al. described an observational 8-year follow-up study on patients treated for AT with many different kinds of treatments including one to three CS injections and found 94% had good or excellent results. Silbernagel et al. did a 5-year follow-up on an efficacy RCT including specific eccentric training for AT and reported 65% were symptom-free, whereas van der Plas et al. on a similar study group found only 39.7% without symptoms at 5-year follow-up. In the present study 63% were symptom-free.

All outcome measures in our primary study were significantly improved, and this was maintained at 10-year follow-up. However the group of patients receiving two CS injections had significantly poorer outcome at 10 years in morning pain and pain during function, although not in VISA-A score compared with the other groups. Also we found that only this group showed a significant increase in tendon thickness from 6 months to 10 years. A higher proportion of patients receiving CS underwent surgery compared with the group without an injection.

This might be due to a deleterious effect of CS reducing collagen synthesis, but can most probably be explained by the fact that patients who were offered CS injections in our study had more severe AT.

**Surgery and tendon ruptures**

A bias to any long-term follow-up is that during a period of 5–10 years patients may have sought other treatments. Paavola et al. reported 29% being operated Silbernagel et al 0% and van der Plas et al 13%. In the present study 16% had surgery. The reasons for these differences could be the selection of patients in the different studies and different inclusion criteria. In our study we included consecutive patients, including patients with insertional tendinopathy.

Tendon ruptures after CS injections are mainly reported in case studies, but in prospective studies only one rupture has been reported. In very long-term follow-up studies, one rupture was described by Paavola et al. in a patient playing soccer 1 week after a...
CS injection. In our study three ruptures were registered over the 10-year period, one of these obtained after aggressive CS injection therapy with six injections in another medical clinic. However, the remaining two ruptures occurred 5–8 years after CS injections. Also two patients in the present study had had pre-existing ruptures at entry without any CS injections and were excluded from our study. We conclude that tendinopathy might lead to rupture, and consider it possible that more than three injections might increase the risk, especially if combined with aggressive rehabilitation. Based on our study we believe that one to three injections combined with reduced loading and controlled exercises is safe, and according to Paavola et al and our primary and present study with good short-term and long-term outcomes.

Insertional and mid-substance tendinopathies

In our study we included both mid-substance and insertional tendinopathies, and in the primary study we found equal effect, with 77% being satisfied with our treatment regimen. However the classic painful eccentric training proved to improve 60%–90% of patients with mid-substance tendinopathy, and only had a good effect in 32% of patients with insertional tendinopathy. Our training regimen started with exercises without dorsiflexion and slowly progressed to dorsiflexed exercises not aggravating pain. In a non-controlled pilot study on patients with insertional AT, 67% of patients were satisfied after performing 12 weeks of eccentric exercises without dorsiflexion. Many studies argue that mid-substance and insertional tendinopathies have different pathology, and therefore exclude insertional tendinopathy in treatment studies; however, the pathology seems similar. AT might also change over time from mid-substance to insertional or vice versa, and Paavola et al describe how three patients in their study changed from mid-substance to insertional tendinopathy during the follow-up period. We did not see that change in our study, but the long-term result was just as good for the insertional tendinopathy as for mid-substance tendinopathy.

Ultrasound scanning

In our primary study population we found that heterogeneity at entry was a prognostic factor for poor outcome, although tendon thickness and Doppler activity at entry could not be used as prognostic markers. In this long-term follow-up, no US changes at entry were found useful as prognostic marker in the very long term. Tendon thickness, increased flow and hypoechogenicity were found to be associated with pain at any given time point in our primary study population. Reiter et al found a positive relationship between the presence of neovascularisation and pain and restricted function on 20 patients, but De Jonge et al could not confirm this finding in a bigger study comprising 556 paired measurements but had dichotomised the flow from Ohberg grades 0–4.

Boesen et al have shown that neovascularisation might be a physiological response to activity. In our study grade 1 flow did not differ in pain and function measured by VISA-A from grade 0, but grades 2–3 had significant lower VISA-A than grade 0. Therefore some degree of flow might be physiological, whereas higher grades of flow might be a sign of pathology.

CONCLUSION

The very long-term follow-up of patients with AT shows that 90% report good or excellent results, although many patients (37%) still have some degree of pain and reduced function after 10 years. We did not find that one to two CS injections increased the risk of tendon rupture, and with the good or excellent very long-term results CS injections do not seem to have a deleterious effect per se. Patients with insertional tendinopathy were operated more often than mid-substance tendinopathy, but otherwise we found no differences in the long-term outcome between these two groups. We found no prognostic parameters at entry for poor outcome, and it seems that an increased tendon thickness is more or less permanent. Higher grades of flow and heterogeneity seem to correspond with poor function and pain.

REFERENCES